Effects of beta-adrenergic inhibition on scar formation after myocardial infarction.
In view of clinical interest in the efficacy of beta-adrenergic blockade during acute myocardial infarction (AMI), we have determined the long-term effect of therapy on scar formation after experimental myocardial ischemia. Intact anesthetized dogs underwent acute occlusion of the left anterior descending coronary artery, by means of a balloon catheter, which permitted monitoring of the aortic-peripheral coronary artery pressure gradient during the 4-hour period of balloon inflation. Practolol administration was begun 15 minutes after the onset of ischemia in group A. Control animals (group B) received procainamide to approximate the antiarrhythmic action of beta blockade. Only group A exhibited significant reduction in the ST segments during acute ischemia. Chronic therapy was maintained for 1 month and the mature scar formed in the myocardium was assessed after 4 months. The extent of subendocardial scar was similar in both groups but subepicardial scar formation was significantly less in group A. There was also a significant decrease in the percentage of total myocardium involved with scar in this treatment group. Although thinning of the left ventricular wall was similar for both groups in the central scar region, this process was significantly reduced at the lateral margin in group A. Thus, specific beta-receptor blockade during acute myocardial ischemia and sustained during the repair process can result in a reduced quantity and altered distribution of mature scar.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000818:Animals; D002921:Cicatrix / Q000209:etiology / Q000473:pathology*; D004285:Dogs; D004562:Electrocardiography; D004699:Endocardium / Q000473:pathology; D006352:Heart Ventricles / Q000473:pathology; D008297:Male; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy / Q000473:pathology* / Q000503:physiopathology; D009206:Myocardium / Q000473:pathology*; D010496:Pericardium / Q000473:pathology; D011217:Practolol / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D011217:Practolol